Market Research Logo

Global Erythropoietin (EPO) Market with Focus on Asia- Industry Analysis & Outlook (2016-2020)

Global Erythropoietin (EPO) Market with Focus on Asia- Industry Analysis & Outlook (2016-2020)

Erythropoietin is a substance produced by the kidney that leads to the formation of red blood cells in the bone marrow. It is a glycoprotein hormone which regulates erythropoiesis (Red Blood Cell production). For erythrocyte precursors present in the bone marrow, EPO acts as a cytokine. Commonly referred to as hematopoietin or hemopoietin, erythropoietin is also known to have other biological functions, such as involvement in the wound healing cycle and brain’s response to neuronal injury. People suffering from End Stage Renal Disease (ESRD), HIV or undergoing chemotherapy are not able to produce enough EPO on their own and thus, are administered with synthetic or recombinant erythropoietin which has the similar sequence of amino acids. Recombinant erythropoietin is a kind of therapeutic agent devised using DNA technology.

On the bases of their molecular structure, EPO drugs can be divided into five categories: epoetin-alfa, epoetin-beta, epoetin-omega, epoetin-delta and darbepoetin-alfa. Among these epoetin-alfa and darbepoetin-alfa are most commonly prescribed EPO drugs.

The global EPO drugs market is expected to experience negative growth rate, primarily due to expiry of patents of two most common EPO drugs, epoetin-alfa and darbepoetin-alfa, allowing the entry of biosimilars; posing a serious threat to EPO drugs market. However, the Asia-Pacific region is expected to experience boom period majorly due to improving disposable income and better government medical reimbursement policies.

The report “Global Erythropoietin (EPO) Market with Focus on Asia: Industry Analysis & Outlook (2016-2020)” analyzes the development of this market, with focus on the US and Asia-Pacific markets. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four major players: Johnson & Johnson, Amgen, Roche and Teva Pharmaceutical Industries Limited are being profiled along with their key financials and strategies for growth. The report contains a comprehensive analysis of the global EPO market along with the study of the regional markets.


1. Overview
1.1 Erythropoietin
Figure 1.1: Erythropoietin Response to Hypoxia
1.2 Recombinant Human Erythropoietin (rHuEPO)
Figure 1.2: Types of Recombinant Human Erythropoietin (rHuEPO)
1.3 Applications of EPO and Adverse Effects
2. Global EPO Market
2.1 Global EPO Drug Market by Value
Figure 2.1: Global EPO Drug Market by Value (2011-2015)
2.2 Global EPO Drug Market Forecast by Value
Figure 2.2: Global EPO Drug Market Forecast by Value (2016-2020)
2.3 Global EPO Biosimilar Market by Value
Figure 2.3: Global EPO Biosimilar Market by Value (2011-2015)
2.4 Global EPO Biosimilar Market Forecast by Value
Figure 2.4: Global EPO Biosimilar Market Forecast by Value (2016-2020)
2.5 Global EPO Market by Drug Type
Figure 2.5: Global EPO Market by Drug Type (2015/2020)
2.6 Global EPO Drug Market Forecast by Application
Figure 2.6: Global EPO Market Forecast by Application (2020)
2.7 Global EPO Drug Market by Region
Figure 2.7: Global EPO Drug Market by Region (2015/2020)
3. Regional EPO Market
3.1 The US
3.1.1 The US EPO Drug Market Forecast by Value
Figure 3.1: The US EPO Drug Market Forecast by Value (2015-2020)
3.1.2 The US EPO Drugs Market by Applications
Figure 3.2: The US EPO Drugs Market by Applications (2015)
3.2 Asia-Pacific
3.2.1 China EPO Drug Market by Value
Figure 3.3: China EPO Drug Market by Value (2011-2015)
3.2.2 China EPO Drug Market Forecast by Value
Figure 3.4: China EPO Drug Market Forecast by Value (2016-2020)
3.2.3 China EPO Drug Market by Application
Figure 3.5: China EPO Drug Market by Application (2015)
3.2.4 Malaysia EPO Drug Market Forecast by Value
Figure 3.6: Malaysia EPO Drug Market Forecast by Value (2015-2020)
3.2.5 Korea EPO Drug Market Forecast by Value
Figure 3.7: Korea EPO Drug Market Forecast by Value (2015-2020)
3.2.6 Thailand EPO Drug Market Forecast by Value
Figure 3.8: Thailand EPO Drug Market Forecast by Value (2015-2020)
3.2.7 Philippines EPO Drug Market Forecast by Value
Figure 3.9: Philippines EPO Drug Market Forecast by Value (2015-2020)
3.2.8 Vietnam EPO Drug Market Forecast by Value
Figure 3.10: Vietnam EPO Drug Market Forecast by Value (2015-2020)
4. Market Dynamics
4.1 Growth Drivers
4.1.1 Rising Number of Patients Suffering from ESRD
Figure 4.1: Global ESRD Patients Volume (2011-2015)
4.1.2 Increasing Global Healthcare Expenditure Per Capita
Figure 4.2: Global Healthcare Expenditure Per Capita (2011-2015)
4.1.3 Rising Global GDP Per Capita
Figure 4.3: Global GDP Per Capita (2011-2015)
4.1.4 Escalating Aged Population
Figure 4.4: Global Population above 64 Years (2011-2015)
4.1.5 Rising Cases of HIV and Cancer Induced Anemia
Figure 4.5: Global New Cancer Patients by Volume (2011-2015)
4.1.6 Increasing Sales of Prescription Drugs
Figure 4.6: Global Sales of Prescription Drugs (2011-2015)
4.2 Trends
4.2.1 Entry of Biosimilar
Table 4.1: EPO Biosimilar and Drugs by Company (2015)
4.2.2 Shift from Short-Acting to Long-Acting EPO Drugs
4.2.3 Underpenetrated Dialysis and Oncology Market in Asia
4.3 Challenges
4.3.1 Biosimilar Hampering the EPO Drug Market Growth
Figure 4.7: Global Biosimilar Market by Value (2011-2015)
4.3.2 Declining Price of EPO drugs
4.3.3 High R&D Cost
5. Competitive Landscape
5.1 Global EPO Drug Market
5.1.1 Global EPO Drugs Market Share by Company
Figure 5.1: Global EPO Drugs Market Share by Company (2015)
5.1.2 Global EPO Drugs Market by Products
Table 5.1: Global EPO Drugs Market Share by Company (2015)
5.2 The US EPO Drug Market
5.2.1 The US EPO Drugs Market Share by Company
Figure 5.2: The US EPO Drugs Market Share by Company (2015)
5.3 Asia-Pacific EPO Drug Market
5.3.1 China EPO Market Share by Company
Figure 5.3: China EPO Market Share by Company (2015)
5.3.2 Japan EPO Market Share by Company
Figure 5.4: Japan Short-Acting EPO Market Share by Company (2015)
6. Company Profiles
6.1 Johnson & Johnson
6.1.1 Business Overview
Figure 6.1: Johnson & Johnson Revenue by Segment (2015)
6.1.2 Financial Overview
Figure 6.2: Johnson & Johnson Revenue and Net Income (2011-2015)
6.1.3 Business Strategies
Figure 6.3: Johnson & Johnson R&D Expenditure (2013-2015)
6.2 Roche Holding AG
6.2.1 Business Overview
Figure 6.4: Roche Holding AG Revenue by Segment (2015)
6.2.2 Financial Overview
Figure 6.5: Roche Holding AG Revenue and Net Income (2011-2015)
6.2.3 Business Strategies
Figure 6.6: Roche Holding AG R&D Expenditure (2013-2015)
6.3 Amgen Inc.
6.3.1 Business Overview
Figure 6.7: Amgen Inc. Revenue by Product Segment (2015)
6.3.2 Financial Overview
Figure 6.8: Amgen Inc. Revenue and Net Income (2011-2015)
6.3.3 Business Strategies
Figure 6.9: Amgen Inc. R&D Expenditure (2013-2015)
6.4 Teva Pharmaceutical Industries Limited
6.4.1 Business Overview
Figure 6.10: Teva Revenue by Segment (2015)
6.4.2 Financial Overview
Figure 6.11: Teva Revenue and Net Income (2011-2015)
6.4.3 Business Strategies
Figure 6.12: Teva’s R&D Expenditure (2013-2015)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report